Abbott Laboratories Inc. announced Jan. 3 immediate U.S. launch of its everolimus-eluting Xience Xpedition next-generation coronary stent system after gaining FDA approval. Xience Xpedition, the newest technology in Illinois-based Abbott’s line of Xience drug-eluting stents, features a new stent delivery system “designed to optimize deliverability, particularly in challenging coronary anatomies,” the firm said in a Jan. 3 press release. Xience stents “are the first and only drug eluting stents in the U.S. market to be proven safe for direct stenting,” the company added.
Indicated for improving coronary artery luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery...